Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-04-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
第四届董事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the board of directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the convening and attendance of the fourth board's eighth meeting, including the approval of the 2022 first quarter report. The document references the actual quarterly report being published separately on the Beijing Stock Exchange website (announcement 2022-046). The text itself does not contain the financial data or the full quarterly report but is an announcement of the board meeting resolutions and approval of the report. The document length is short (900 characters), and it serves as a formal announcement of the board meeting decisions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and board meeting resolution notice, not as the Interim/Quarterly Report (IR) itself.
2022-04-21 Chinese
2021 年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2021 annual equity distribution (dividend) plan of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the dividend amount, tax withholding policies, record date, ex-dividend date, and payment method. The document is short (1224 characters) and focuses on dividend distribution details rather than presenting financial statements or comprehensive financial performance. It is not a full annual report or earnings release but a specific announcement about dividend payment. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-04-14 Chinese
广东君信律师事务所关于广东永顺生物制药股份有限公司2021 年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the 2021 Annual General Meeting (AGM) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on various proposals including the 2021 annual report and financial statements, and confirms the legality and validity of the meeting procedures. The document does not contain the actual annual report or financial statements but rather the legal opinion on the AGM process and voting outcomes. The document length is under 5,000 characters and is focused on the AGM event and voting results. Therefore, it fits best as a Declaration of Voting Results & Voting Rights Announcement (DVA).
2022-04-13 Chinese
2021 年年度股东大会决议公告
AGM Information Classification · 100% confidence The document is titled as a resolution announcement from the Annual General Meeting (AGM) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions related to the 2021 fiscal year. The content focuses on the decisions made during the AGM, including approval of reports, financial budgets, dividend distribution plans, credit applications, and auditor reappointment. It does not contain the full annual report or financial statements but references them as disclosed elsewhere. The document is a formal announcement of the AGM resolutions rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2022-04-13 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and specifically mentions it is an "业绩说明会" (Earnings Explanation Meeting) held on April 8, 2022, regarding the 2021 Annual Report. The content includes detailed Q&A about the company's 2021 financial performance, business strategy, product development, and market outlook. This matches the characteristics of a Call Transcript (CT) or Earnings Call Transcript, as it records the questions from investors and the company's responses in detail. The document length is 3460 characters, which is consistent with a transcript rather than a brief announcement or presentation. It is not a full Annual Report (10-K) or an Earnings Release (ER) since it contains detailed Q&A rather than just highlights. Therefore, the best classification is Call Transcript (CT).
2022-04-07 Chinese
2021 年年度报告说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled annual report earnings presentation (an 'annual report performance explanation meeting') for the 2021 fiscal year. It references the 2021 Annual Report already published on March 23, 2022, and invites investors to participate in a webcast on April 8, 2022. The document does not contain the annual report itself or detailed financial data, but rather announces the upcoming investor presentation related to the annual report. The document length is short (919 characters), consistent with an announcement rather than a full report. Therefore, it fits the category of Investor Presentation (IP) as it is a detailed presentation event for investors focusing on financial results and company performance.
2022-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.